1. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review 
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A. Schalken, Francesco Montorsi, Piotr L. Chlosta, Axel Heidenreich 
European Urology Supplements 
Volume 9, Issue 7, Pages (October 2010)
DOI: /j.eursup
Copyright © 2010 European Association of Urology Terms and Conditions

2. Fig. 1
Overall survival with external-beam radiation therapy (EBRT) plus androgen-deprivation therapy (n=207) versus EBRT alone (n=208) in high-risk localised or locally advanced prostate cancer. Reproduced with permission from Bolla et al [3].
CI=confidence interval; N=number of patients; O=number of deaths.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

3. Fig. 2
Survival free from clinical metastasis with early androgen-deprivation therapy (ADT) initiated at prostate-specific antigen (PSA) ≤5 ng/ml versus late ADT in patients with biochemical recurrence following definitive local therapy and Gleason score >7 or PSA doubling time ≤12 mo (n=343). Reproduced with permission from Moul et al [46].
HT=hormonal therapy.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

4. Fig. 3
Mean testosterone levels in five studies of patients treated with bilateral orchidectomy [49,50–53]. Reproduced with permission from Tombal and Berges [54].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

5. Fig. 4
Survival free from androgen-independent progression in patients with all three testosterone determinations <20 ng/dl (group 1), patients with breakthrough increases 20–50 ng/dl (group 2), and patients with breakthrough increases >50 ng/dl (group 3). Reproduced with permission from Morote et al [58].
ADT=androgen-deprivation therapy; PSA=prostate-specific antigen.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

6. Fig. 5
Overall survival with continuous (n=312) versus intermittent (n=314) androgen-deprivation therapy in patients with locally advanced or metastatic prostate cancer. Reproduced with permission from Calais da Silva et al [72].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

7. Fig. 6
Kaplan-Meier estimate of probability of cardiovascular events over time in an observational study of men with prostate cancer who received androgen-deprivation therapy (ADT) (n=4810) or did not receive ADT (n=18 006). Reproduced with permission from Saigal et al [87].
CL=confidence limit; NA=not applicable.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions